Cargando…
The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans
Cardiovascular disease (CVD) is the leading cause of death globally. It is well-established based on evidence accrued during the last three decades that high plasma concentrations of cholesterol-rich atherogenic lipoproteins are causatively linked to CVD, and that lowering these reduces atherosclero...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7399058/ https://www.ncbi.nlm.nih.gov/pubmed/32849270 http://dx.doi.org/10.3389/fendo.2020.00474 |
_version_ | 1783566074024820736 |
---|---|
author | Borén, Jan Packard, Chris J. Taskinen, Marja-Riitta |
author_facet | Borén, Jan Packard, Chris J. Taskinen, Marja-Riitta |
author_sort | Borén, Jan |
collection | PubMed |
description | Cardiovascular disease (CVD) is the leading cause of death globally. It is well-established based on evidence accrued during the last three decades that high plasma concentrations of cholesterol-rich atherogenic lipoproteins are causatively linked to CVD, and that lowering these reduces atherosclerotic cardiovascular events in humans (1–9). Historically, most attention has been on low-density lipoproteins (LDL) since these are the most abundant atherogenic lipoproteins in the circulation, and thus the main carrier of cholesterol into the artery wall. However, with the rise of obesity and insulin resistance in many populations, there is increasing interest in the role of triglyceride-rich lipoproteins (TRLs) and their metabolic remnants, with accumulating evidence showing they too are causatively linked to CVD. Plasma triglyceride, measured either in the fasting or non-fasting state, is a useful index of the abundance of TRLs and recent research into the biology and genetics of triglyceride heritability has provided new insight into the causal relationship of TRLs with CVD. Of the genetic factors known to influence plasma triglyceride levels variation in APOC3- the gene for apolipoprotein (apo) C-III - has emerged as being particularly important as a regulator of triglyceride transport and a novel therapeutic target to reduce dyslipidaemia and CVD risk (10). |
format | Online Article Text |
id | pubmed-7399058 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-73990582020-08-25 The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans Borén, Jan Packard, Chris J. Taskinen, Marja-Riitta Front Endocrinol (Lausanne) Endocrinology Cardiovascular disease (CVD) is the leading cause of death globally. It is well-established based on evidence accrued during the last three decades that high plasma concentrations of cholesterol-rich atherogenic lipoproteins are causatively linked to CVD, and that lowering these reduces atherosclerotic cardiovascular events in humans (1–9). Historically, most attention has been on low-density lipoproteins (LDL) since these are the most abundant atherogenic lipoproteins in the circulation, and thus the main carrier of cholesterol into the artery wall. However, with the rise of obesity and insulin resistance in many populations, there is increasing interest in the role of triglyceride-rich lipoproteins (TRLs) and their metabolic remnants, with accumulating evidence showing they too are causatively linked to CVD. Plasma triglyceride, measured either in the fasting or non-fasting state, is a useful index of the abundance of TRLs and recent research into the biology and genetics of triglyceride heritability has provided new insight into the causal relationship of TRLs with CVD. Of the genetic factors known to influence plasma triglyceride levels variation in APOC3- the gene for apolipoprotein (apo) C-III - has emerged as being particularly important as a regulator of triglyceride transport and a novel therapeutic target to reduce dyslipidaemia and CVD risk (10). Frontiers Media S.A. 2020-07-28 /pmc/articles/PMC7399058/ /pubmed/32849270 http://dx.doi.org/10.3389/fendo.2020.00474 Text en Copyright © 2020 Borén, Packard and Taskinen. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Borén, Jan Packard, Chris J. Taskinen, Marja-Riitta The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans |
title | The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans |
title_full | The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans |
title_fullStr | The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans |
title_full_unstemmed | The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans |
title_short | The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans |
title_sort | roles of apoc-iii on the metabolism of triglyceride-rich lipoproteins in humans |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7399058/ https://www.ncbi.nlm.nih.gov/pubmed/32849270 http://dx.doi.org/10.3389/fendo.2020.00474 |
work_keys_str_mv | AT borenjan therolesofapociiionthemetabolismoftriglyceriderichlipoproteinsinhumans AT packardchrisj therolesofapociiionthemetabolismoftriglyceriderichlipoproteinsinhumans AT taskinenmarjariitta therolesofapociiionthemetabolismoftriglyceriderichlipoproteinsinhumans AT borenjan rolesofapociiionthemetabolismoftriglyceriderichlipoproteinsinhumans AT packardchrisj rolesofapociiionthemetabolismoftriglyceriderichlipoproteinsinhumans AT taskinenmarjariitta rolesofapociiionthemetabolismoftriglyceriderichlipoproteinsinhumans |